Divi's Laboratories Q1 FY27 Profit Surges 66% to ₹902 Crore as Revenue Climbs 28%
Key Takeaways
- •Divi's Laboratories recorded a 65.6% year-over-year increase in net profit to ₹902 crore for the first quarter of fiscal year 2027.
- •Revenue from operations grew 27.8% to ₹3,080 crore, exceeding market estimates.
- •The EBITDA margin expanded from approximately 30.3% to 40.7%, driven by improved cost efficiency and a favorable product mix.
- •The Hyderabad-based company is a leading global API manufacturer that has benefited from multinational pharmaceutical firms diversifying sourcing under the China-plus-one supply chain strategy.
- •Divi's Laboratories is a constituent of the NIFTY 50 index and trades on both the NSE and BSE under the ticker DIVISLAB.
Divi's Laboratories Q1 FY27 Profit Surges 66% to ₹902 Crore as Revenue Climbs 28%
Divi's Laboratories reported strong financial results for the first quarter of fiscal year 2027, with net profit rising 65.6% year-over-year to ₹902 crore. The company's revenue from operations grew 27.8% to ₹3,080 crore, exceeding market estimates.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) jumped 72.2% to ₹1,255 crore during the quarter, reflecting a significant improvement in operating profitability. The EBITDA margin expanded to approximately 40.7%, compared to roughly 30.3% in the year-ago period, indicating meaningful gains in cost efficiency and product mix.
Divi's Laboratories is one of India's largest pharmaceutical companies and a globally recognized manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Headquartered in Hyderabad, the company supplies APIs to generic drug makers worldwide and is also involved in custom synthesis and nutraceutical ingredients. India is a global hub for generic drug and API manufacturing, and companies like Divi's have benefited as multinational pharmaceutical firms have diversified their API sourcing beyond China in recent years—a trend often referred to as the China-plus-one supply chain strategy. The stock is a constituent of the NIFTY 50 index and trades on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) under the ticker DIVISLAB.
The Q1 FY27 results were reported by CNNBC-TV18 Markets on August 1, 2026.